Kunihiro Matsushita1, Yingying Sang2, Shoshana H Ballew2, Brad C Astor2, Ron C Hoogeveen2, Scott D Solomon2, Christie M Ballantyne2, Mark Woodward2, Josef Coresh2. 1. From the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (K.M., Y.S., S.H.B., M.W., J.C.); Department of Medicine and Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison (B.C.A.); Department of Medicine, Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, and the Methodist DeBakey Heart and Vascular Center, Houston, TX (R.C.H., C.M.B.); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D.S.). kmatsush@jhsph.edu. 2. From the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (K.M., Y.S., S.H.B., M.W., J.C.); Department of Medicine and Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison (B.C.A.); Department of Medicine, Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, and the Methodist DeBakey Heart and Vascular Center, Houston, TX (R.C.H., C.M.B.); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D.S.).
Abstract
OBJECTIVE: Traditional predictors suboptimally predict cardiovascular disease (CVD) in individuals with chronic kidney disease (CKD). This study compared 5 nontraditional cardiac and kidney markers on the improvement of cardiovascular prediction among those with CKD. APPROACH AND RESULTS: Among 8622 participants aged 52 to 75 years in the Atherosclerosis Risk in Communities (ARIC) Study, cardiac troponin T, N-terminal pro-B-type natriuretic peptide, cystatin C, β2-microglobulin, and β-trace protein were compared for improvement in predicting incident CVD after stratifying by CKD status (940 participants with CKD [kidney dysfunction or albuminuria]). During a median follow-up of 11.9 years, there were 1672 CVD events including coronary disease, stroke, and heart failure (336 cases in CKD). Every marker was independently associated with incident CVD in participants with and without CKD. The adjusted hazard ratios (per 1 SD) were larger for cardiac markers than for kidney markers, particularly in CKD (1.61 [95% confidence interval, 1.43-1.81] for cardiac troponin T, 1.50 [1.34-1.68] for N-terminal pro-B-type natriuretic peptide, and <1.26 for kidney markers). Particularly in CKD group, cardiac markers compared with kidney markers contributed to greater c-statistic increment (0.032-0.036 versus 0.012-0.015 from 0.679 with only conventional predictors in CKD and 0.008-0.011 versus 0.002-0.010 from 0.697 in non-CKD) and categorical net reclassification improvement (0.086-0.127 versus 0.020-0.066 in CKD and 0.057-0.077 versus 0.014-0.048 in non-CKD). The superiority of cardiac markers was largely consistent in individual CVD outcomes. CONCLUSIONS: A greater improvement in cardiovascular prediction was observed for cardiac markers than for kidney markers in people with CKD. These results suggest that cardiac troponin T and N-terminal pro-B-type natriuretic peptide are useful for better CVD risk classification in this population.
OBJECTIVE: Traditional predictors suboptimally predict cardiovascular disease (CVD) in individuals with chronic kidney disease (CKD). This study compared 5 nontraditional cardiac and kidney markers on the improvement of cardiovascular prediction among those with CKD. APPROACH AND RESULTS: Among 8622 participants aged 52 to 75 years in the Atherosclerosis Risk in Communities (ARIC) Study, cardiac troponin T, N-terminal pro-B-type natriuretic peptide, cystatin C, β2-microglobulin, and β-trace protein were compared for improvement in predicting incident CVD after stratifying by CKD status (940 participants with CKD [kidney dysfunction or albuminuria]). During a median follow-up of 11.9 years, there were 1672 CVD events including coronary disease, stroke, and heart failure (336 cases in CKD). Every marker was independently associated with incident CVD in participants with and without CKD. The adjusted hazard ratios (per 1 SD) were larger for cardiac markers than for kidney markers, particularly in CKD (1.61 [95% confidence interval, 1.43-1.81] for cardiac troponin T, 1.50 [1.34-1.68] for N-terminal pro-B-type natriuretic peptide, and <1.26 for kidney markers). Particularly in CKD group, cardiac markers compared with kidney markers contributed to greater c-statistic increment (0.032-0.036 versus 0.012-0.015 from 0.679 with only conventional predictors in CKD and 0.008-0.011 versus 0.002-0.010 from 0.697 in non-CKD) and categorical net reclassification improvement (0.086-0.127 versus 0.020-0.066 in CKD and 0.057-0.077 versus 0.014-0.048 in non-CKD). The superiority of cardiac markers was largely consistent in individual CVD outcomes. CONCLUSIONS: A greater improvement in cardiovascular prediction was observed for cardiac markers than for kidney markers in people with CKD. These results suggest that cardiac troponin T and N-terminal pro-B-type natriuretic peptide are useful for better CVD risk classification in this population.
Authors: Olle Melander; Christopher Newton-Cheh; Peter Almgren; Bo Hedblad; Göran Berglund; Gunnar Engström; Margaretha Persson; J Gustav Smith; Martin Magnusson; Anders Christensson; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Michael J Pencina; Thomas J Wang Journal: JAMA Date: 2009-07-01 Impact factor: 56.272
Authors: Lieneke Scheven; Paul E de Jong; Hans L Hillege; Hiddo J Lambers Heerspink; L Joost van Pelt; Jenny E Kootstra; Stephan J L Bakker; Ron T Gansevoort Journal: Eur Heart J Date: 2012-06-27 Impact factor: 29.983
Authors: Catherine M Clase; Peggy Gao; Sheldon W Tobe; Matthew J McQueen; Anja Grosshennig; Koon K Teo; Salim Yusuf; Johannes F E Mann Journal: Ann Intern Med Date: 2011-03-01 Impact factor: 25.391
Authors: Jasmin Amighi; Matthias Hoke; Wolfgang Mlekusch; Oliver Schlager; Markus Exner; Markus Haumer; Elisabeth Pernicka; Renate Koppensteiner; Erich Minar; Helmut Rumpold; Martin Schillinger; Oswald Wagner Journal: Stroke Date: 2011-05-05 Impact factor: 7.914
Authors: Björn Zethelius; Lars Berglund; Johan Sundström; Erik Ingelsson; Samar Basu; Anders Larsson; Per Venge; Johan Arnlöv Journal: N Engl J Med Date: 2008-05-15 Impact factor: 91.245
Authors: Daniel E Weiner; Hocine Tighiouart; Essam F Elsayed; John L Griffith; Deeb N Salem; Andrew S Levey; Mark J Sarnak Journal: J Am Coll Cardiol Date: 2007-07-02 Impact factor: 24.094
Authors: Stephen Kaptoge; Emanuele Di Angelantonio; Lisa Pennells; Angela M Wood; Ian R White; Pei Gao; Matthew Walker; Alexander Thompson; Nadeem Sarwar; Muriel Caslake; Adam S Butterworth; Philippe Amouyel; Gerd Assmann; Stephan J L Bakker; Elizabeth L M Barr; Elizabeth Barrett-Connor; Emelia J Benjamin; Cecilia Björkelund; Hermann Brenner; Eric Brunner; Robert Clarke; Jackie A Cooper; Peter Cremer; Mary Cushman; Gilles R Dagenais; Ralph B D'Agostino; Rachel Dankner; George Davey-Smith; Dorly Deeg; Jacqueline M Dekker; Gunnar Engström; Aaron R Folsom; F Gerry R Fowkes; John Gallacher; J Michael Gaziano; Simona Giampaoli; Richard F Gillum; Albert Hofman; Barbara V Howard; Erik Ingelsson; Hiroyasu Iso; Torben Jørgensen; Stefan Kiechl; Akihiko Kitamura; Yutaka Kiyohara; Wolfgang Koenig; Daan Kromhout; Lewis H Kuller; Debbie A Lawlor; Tom W Meade; Aulikki Nissinen; Børge G Nordestgaard; Altan Onat; Demosthenes B Panagiotakos; Bruce M Psaty; Beatriz Rodriguez; Annika Rosengren; Veikko Salomaa; Jussi Kauhanen; Jukka T Salonen; Jonathan A Shaffer; Steven Shea; Ian Ford; Coen D A Stehouwer; Timo E Strandberg; Robert W Tipping; Alberto Tosetto; Sylvia Wassertheil-Smoller; Patrik Wennberg; Rudi G Westendorp; Peter H Whincup; Lars Wilhelmsen; Mark Woodward; Gordon D O Lowe; Nicholas J Wareham; Kay-Tee Khaw; Naveed Sattar; Chris J Packard; Vilmundur Gudnason; Paul M Ridker; Mark B Pepys; Simon G Thompson; John Danesh Journal: N Engl J Med Date: 2012-10-04 Impact factor: 91.245
Authors: Puneeta Tandon; Navdeep Tangri; Lesley Thomas; Laura Zenith; Tahira Shaikh; Michelle Carbonneau; Mang Ma; Robert J Bailey; Saumya Jayakumar; Kelly W Burak; Juan G Abraldes; Amanda Brisebois; Thomas Ferguson; Sumit R Majumdar Journal: Am J Gastroenterol Date: 2016-08-02 Impact factor: 10.864
Authors: Lene Ryom; Jens D Lundgren; Mike Ross; Ole Kirk; Matthew Law; Philippe Morlat; Eric Fontas; Colette Smit; Christoph A Fux; Camilla I Hatleberg; Stéphane de Wit; Caroline A Sabin; Amanda Mocroft Journal: J Infect Dis Date: 2016-08-02 Impact factor: 5.226
Authors: Caitlin W Hicks; Dan Wang; Natalie R Daya; B Gwen Windham; Christie M Ballantyne; Kunihiro Matsushita; Elizabeth Selvin Journal: Clin Chem Date: 2020-05-01 Impact factor: 8.327
Authors: Kunihiro Matsushita; Lucia Kwak; Shoshana H Ballew; Morgan E Grams; Elizabeth Selvin; Aaron R Folsom; Josef Coresh; Weihong Tang Journal: Atherosclerosis Date: 2018-09-01 Impact factor: 5.162
Authors: Kathrin Untersteller; Nicolas Girerd; Kevin Duarte; Kyrill S Rogacev; Sarah Seiler-Mussler; Danilo Fliser; Patrick Rossignol; Gunnar H Heine Journal: Clin J Am Soc Nephrol Date: 2016-08-11 Impact factor: 8.237